Skip to main content
Home
  • Solutions
    Clinical solutions
    Blended Solutions Cardiac Safety Solutions Clinical & Scientific Operations Decentralised Clinical Trials Early Clinical Laboratories Medical Imaging Site & Patient Solutions Strategic Solutions
    Consulting & Commercial
    Asset Development Consulting Commercial Positioning Language Services Outcome Measures Real World Intelligence Regulatory Affairs Symphony Health data
    meeting
    Case studies

    Reducing time to market, delivering on quality, providing deep therapeutic expertise and enhancing R&D ROI.

    Innovative research tools showcase
    Technologies

    Technology solutions from early phase through to post-marketing.

  • Sectors
    Sectors

    ICON provides its full range of clinical, consulting and commercial services across several industry sectors.

    Read more
    Biotech Government and Public Health Medical Device Pharmaceuticals
    Biotechnology services navigation panel
    Biotech

    Developing transformative therapies requires a flexible approach.

    Employee engagement program overview
    ICON and You

    Partners making a difference.

  • Therapeutics
    Therapeutics
    Cardiovascular Central Nervous System Endocrine & Metabolic Disorders Hepatology Infectious Diseases Internal Medicine & Immunology Oncology
    Cross-therapeutics
    Biosimilars Cell and Gene Therapies Medical Device Pediatrics Rare & Orphan Diseases Vaccines Women's Health
    Obesity 2025 insights image
    Obesity

    A focus on combination therapies requires appropriate obesity-specific trial designs, long-term follow-up studies and diverse patient recruitment.

    Biological research visual element
    Therapeutics insights

    ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.

  • Insights
    Insights
    Digital Disruption Patient Centricity Regulatory Intelligence Therapeutics insights Transforming Trials Value Based Healthcare Blog Videos Webinar Channel
    banners
    From bottlenecks to breakthroughs

    Human-centred strategies for faster study starts

    More than monitoring whitepaper
    More than monitoring

    How modern monitoring paradigms impact CRA roles

    digital globe network with icons
    Meeting requirements for Joint Clinical Assessments

    A planning guide for health technology developers

  • News & Events
    News & Events

    ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.

    Read more
    Press releases In the News Mediakit Awards Events Webinars Social media
    webinar
    Best practices in global flow cytometry quality control and harmonisation

    5 March 2026. Register today.

    webinar
    When patients lead: Breaking barriers in ultra-rare disease drug development

    3 March 2026. Register today.

  • About ICON
    About ICON
    Company history ICON at a glance ICON in Asia Pacific ICON in Latin America Leadership Quality
    ICON for
    Patients Volunteers Investigators Jobs & Careers Investors Suppliers
    Responsible business practice indicators
    Sustainability, charity, inclusion and belonging

    ICON Cares is our commitment to making a positive impact on our people, environment and our community.

    Modern reception area at Dublin office
    ICON at a glance

    Delivering successful outcomes across the clinical development lifecycle.

  • Careers
  • Investors
  • Contact
  • 日本語
  • 简体中文
  1. Home
  2. News & Events
  3. Social media

Social media

Page tools
Share Share
Facebook

Share on Facebook

Facebook

Share on X

Facebook

Share on Linkedin

Bluesky

Share on Bluesky

Showing 109 - 120 of 955 results for "*"

Social media image
ICON Plc logo
ICON Plc

At ICON, we understand that exploring a new career opportunity comes with questions. Having a clear sense of what to expect can make the experience feel more straightforward. This week, we’re sharing a five part series ...

26 Jan
ICON Plc facebook post
ICON Plc logo
ICON Plc

At ICON, we understand that exploring a new career opportunity comes with questions. Having a clear sense of what to expect can make the experience feel more straightforward. This week, we’re sharing a five part series ...

26 Jan
4
Social media image
ICON Plc logo
ICON Plc

The development of longer-acting and more potent NUSH receptor agonists, like semaglutide, has helped clarify the link between aberrant glucose metabolism and a range of diseases. Learn how to embrace the multi-indicatio...

23 Jan
ICON Plc facebook post
ICON Plc logo
ICON Plc

The development of longer-acting and more potent NUSH receptor agonists, like semaglutide, has helped clarify the link between aberrant glucose metabolism and a range of diseases. Learn how to embrace the multi-indicatio...

23 Jan
2
Social media image
ICON Plc logo
ICON Plc

PubsHub Journals & Congresses now includes publication AI policy guidelines, ensuring ethical use and transparency in research. Whether you use AI to analyze data or draft manuscripts, learn what’s required for complianc...

22 Jan
ICON Plc facebook post
ICON Plc logo
ICON Plc

PubsHub Journals & Congresses now includes publication AI policy guidelines, ensuring ethical use and transparency in research. Whether you use AI to analyze data or draft manuscripts, learn what’s required for complianc...

22 Jan
2
Social media image
ICON Plc logo
ICON Plc

ICON is heading to SCOPE 2026 From labs and patient solutions to site strategies and biosimilars, our experts will be on the ground in Orlando from 2–5 February. We’re ready to share insights on accelerating clinical de...

21 Jan
ICON Plc facebook post
ICON Plc logo
ICON Plc

ICON is heading to SCOPE 2026 From labs and patient solutions to site strategies and biosimilars, our experts will be on the ground in Orlando from 2–5 February. We’re ready to share insights on accelerating clinical de...

21 Jan
6
Social media image
ICON Plc logo
ICON Plc

To unlock the full value of emerging multi-indication therapies, developers must adopt strategies that prioritise early cross-functional planning and innovative trial architecture. ICON’s Jack Martin and Alan Baldridge...

21 Jan
ICON Plc facebook post
ICON Plc logo
ICON Plc

To unlock the full value of emerging multi-indication therapies, developers must adopt strategies that prioritise early cross-functional planning and innovative trial architecture. ICON’s Jack Martin and Alan Baldridge...

21 Jan
4
Social media image
ICON Plc logo
ICON Plc

Product labelling and promotional materials are the foundation of pharma communication and effective pharmaceutical communications begin with a strategic vision anchored in the product label. Regulatory change often br...

21 Jan
ICON Plc facebook post
ICON Plc logo
ICON Plc

When policy shifts hit, precision wins. Tip: Monitor competitor labels, tighten MLR collaboration and track OPDP’s enforcement focus on social and DTC to keep promotion both compelling and compliant. To dive deeper, rea...

21 Jan
  • Previous
  • 1
  • …
  • 9
  • 10
  • 11
  • …
  • 80
  • Next
Filter by:

Filter by:

Site Branding
    ICON plc
  • Contact
  • About ICON
  • Results & Reports
For Clients
  • Therapeutics
  • Solutions
  • Insights
  • Technologies
  • Content preferences
  • Office locations
ICON for
  • Patients
  • Volunteers
  • Investigators
  • Jobs & Careers
  • Investors
  • Suppliers
News & Events
  • Press releases
  • Mediakit
  • Events
  • Webinars
Socials
  • Linkedin
  • Facebook
  • Instagram
  • Youtube

Legal Footer

  • © 2026 ICON plc
  • Disclaimer
  • Privacy & Data
  • Cookies
How can we help?
  • All
  • Website
Popular search terms:
  • Biotech
  • Cell and Gene Therapies
  • Consulting
  • Early Clinical
  • Medical Device
  • Oncology
  • Rare & Orphan Diseases
  • Real World Evidence
  • Site & Patient Recruitment
  • Strategic Solutions
  • Regulatory Intelligence